This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bulitta, J. B.
Right arrow Articles by Tsuji, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bulitta, J. B.
Right arrow Articles by Tsuji, B. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2009, p. 46-56, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00489-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa{triangledown}

Jürgen B. Bulitta,* Neang S. Ly, Jenny C. Yang,{dagger} Alan Forrest, William J. Jusko, and Brian T. Tsuji

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14260

Received 15 April 2008/ Returned for modification 20 July 2008/ Accepted 8 October 2008

Evidence is mounting in support of the inoculum effect (i.e., slow killing at large initial inocula [CFUo]) for numerous antimicrobials against a variety of pathogens. Our objectives were to (i) determine the impact of the CFUo of Pseudomonas aeruginosa on ceftazidime activity and (ii) to develop and validate a pharmacokinetic/pharmacodynamic (PKPD) mathematical model accommodating a range of CFUo. Time-kill experiments using ceftazidime at seven concentrations up to 128 mg/liter (MIC, 2 mg/liter) were performed in duplicate against P. aeruginosa PAO1 at five CFUo from 105 to 109 CFU/ml. Samples were collected over 24 h and fit by candidate models in NONMEM VI and S-ADAPT 1.55 (all data were comodeled). External model qualification integrated data from eight previously published studies. Ceftazidime displayed approximately 3 to 4 log10 CFU/ml net killing at 106.2 CFUo and concentrations of 4 mg/liter (or higher), less than 1.6 log10 CFU/ml killing at 107.3 CFUo, and no killing at 108.0 CFUo for concentrations up to 128 mg/liter. The proposed mechanism-based model successfully described the inoculum effect and the concentration-independent lag time of killing. The mean generation time was 28.3 min. The effect of an autolysin was assumed to inhibit successful replication. Ceftazidime concentrations of 0.294 mg/liter stimulated the autolysin effect by 50%. The model was predictive in the internal cross-validation and had excellent in silico predictive performance for published studies of P. aeruginosa ATCC 27853 for various CFUo. The proposed PKPD model successfully described and predicted the pronounced inoculum effect of ceftazidime in vitro and integrated data from eight literature studies to support translation from time-kill experiments to in vitro infection models.

* Corresponding author. Mailing address: Department of Pharmaceutical Sciences, Hochstetter Hall, Room 565b, SUNY/Buffalo, Buffalo, NY 14260-1200. Phone: (716) 645-2855, ext. 281. Fax: (716) 645-3693. E-mail: j{at}bulitta.com

{triangledown} Published ahead of print on 13 October 2008.

{dagger} Present address: Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Antimicrobial Agents and Chemotherapy, January 2009, p. 46-56, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00489-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»